Skip to main content
. 2019 Apr 4;4(7):e127001. doi: 10.1172/jci.insight.127001

Figure 2. Treatment with an anti–α4 integrin mAb shows no efficacy in the PCD model.

Figure 2

(A) Tumor size, (B) mouse weight loss, and (C) rotarod cumulative score (left) and performance on day 20 (right) of L7-HA-PCD mice treated with PS/2 (anti–α4 integrin mAb) or control IgG2b from day 10 after the induction of disease onward (n = 8/group, 2 independent experiments). (D) Left: representative staining for calbindin (violet) and nuclear counterstaining with hematoxylin (blue) on cerebellar sections from a control WT mouse, and from L7-HA-PCD mice treated with isotype control or PS/2. Scale bar: 100 μm. Right: quantitative assessment of Purkinje cell density in L7-HA-PCD mice treated with IgG2b or PS/2 (n = 8/group, 2 independent experiments). The shaded area represents the normal range in WT mice, meaning mean ± 2SD.